Pfizer partners with molecular glue startup Triana in $49M upfront deal

Ryan Cross

Senior Science Correspondent

Pfizer is deepening its investment in protein degraders through a new partnership with Triana Biomedicines, a startup working in the trendy field of molecular glues …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer partners with molecular glue startup Triana in $49M upfront deal

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Pfiz­er part­ners with mol­e­c­u­lar glue start­up Tri­ana in $49M up­front deal

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA says Ozem­pic, We­govy short­age is over

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

Pfizer partners with molecular glue startup Triana in $49M upfront deal

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence